Relative versus absolute standards for everyday risk in adolescent HIV prevention trials: expanding the debate
- PMID: 21678205
- DOI: 10.1080/15265161.2011.568576
Relative versus absolute standards for everyday risk in adolescent HIV prevention trials: expanding the debate
Abstract
The concept of minimal risk has been used to regulate and limit participation by adolescents in clinical trials. It can be understood as setting an absolute standard of what risks are considered minimal or it can be interpreted as relative to the actual risks faced by members of the host community for the trial. While commentators have almost universally opposed a relative interpretation of the environmental risks faced by potential adolescent trial participants, we argue that the ethical concerns against the relative standard may not be as convincing as these commentators believe. Our aim is to present the case for a relative standard of environmental risk in order to open a debate on this subject. We conclude by discussing how a relative standard of environmental risk could be defended in the specific case of an HIV vaccine trial among adolescents in South Africa.
Comment in
-
Response to Open Peer Commentaries on "Relative versus absolute standards for everyday risk in adolescent HIV prevention trials: expanding the debate".Am J Bioeth. 2011 Jun;11(6):W1-3. doi: 10.1080/15265161.2011.578477. Am J Bioeth. 2011. PMID: 21678202 No abstract available.
-
A relative standard for minimal risk is unnecessary and potentially harmful to children: lessons from the Phambili trial.Am J Bioeth. 2011 Jun;11(6):14-6. doi: 10.1080/15265161.2011.568588. Am J Bioeth. 2011. PMID: 21678206 No abstract available.
-
(Un)risky business: adolescents and HIV prevention trials.Am J Bioeth. 2011 Jun;11(6):17-9. doi: 10.1080/15265161.2011.568585. Am J Bioeth. 2011. PMID: 21678207 No abstract available.
-
Reopening old divisions.Am J Bioeth. 2011 Jun;11(6):19-21. doi: 10.1080/15265161.2011.566670. Am J Bioeth. 2011. PMID: 21678208 Free PMC article. No abstract available.
-
Why we don't need a relative risk standard for adolescent HIV vaccine trials in South Africa.Am J Bioeth. 2011 Jun;11(6):21-2. doi: 10.1080/15265161.2011.566671. Am J Bioeth. 2011. PMID: 21678209 No abstract available.
-
The dangers of using a relative risk standard for minimal risk.Am J Bioeth. 2011 Jun;11(6):22-3. doi: 10.1080/15265161.2011.572511. Am J Bioeth. 2011. PMID: 21678210 No abstract available.
-
Uniqueness, exploitation, and relative risk standards in adolescent research.Am J Bioeth. 2011 Jun;11(6):23-5. doi: 10.1080/15265161.2011.568587. Am J Bioeth. 2011. PMID: 21678211 No abstract available.
-
Minimal risk remains an open question.Am J Bioeth. 2011 Jun;11(6):25-7. doi: 10.1080/15265161.2011.568579. Am J Bioeth. 2011. PMID: 21678212 No abstract available.
-
The concept of minimal risk: the need for better guidance on the ethics review process.Am J Bioeth. 2011 Jun;11(6):27-9. doi: 10.1080/15265161.2011.568584. Am J Bioeth. 2011. PMID: 21678213 No abstract available.
-
Regulating "higher risk, no direct benefit" studies in minors.Am J Bioeth. 2011 Jun;11(6):29-31. doi: 10.1080/15265161.2011.566669. Am J Bioeth. 2011. PMID: 21678214 No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical